Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 556.24 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; hypromellose; macrogol 400; polysorbate 80 - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 1112.48 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: hypromellose; maize starch; magnesium stearate; croscarmellose sodium; macrogol 400; titanium dioxide; lactose monohydrate; polysorbate 80; povidone - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 556.24 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; macrogol 400; hypromellose; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; lactose monohydrate - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - valaciclovir hydrochloride, quantity: 1112.55 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see section 4.4 special warnings and precautions for use). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556.24 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; crospovidone; povidone; magnesium stearate; titanium dioxide; polyvinyl alcohol; macrogol 3350 - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir arrow, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - valaciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valaciclovir hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valaciclovir hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride, quantity: 611.22 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaclovir, it is recommended that patients use safer sex practices (see section 4.4). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride, quantity: 611.22 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaclovir, it is recommended that patients use safer sex practices (see section 4.4). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.